Alzheimer Breakthrough Disillusionment: Confusion on FDA’s Approval of Expensive and Possibly Ineffective Drug

Share on Facebook
Share on Twitter
Share on
LinkedIn
+

Hubwonk host Joe Selvaggi talks with precision medicine expert Hannah Mamuszka and Pioneer Institute’s Bill Smith about the promises and pitfalls of the newly approved Alzheimer’s drug Aduhelm, and the challenges presented when new, expensive drugs of dubious benefit are introduced to the nation’s formulary.

Guest:

Hannah Mamuszka is Founder & CEO of ALVA10, a healthcare technology firm. Hannah has spent her 20+ year career in diagnostics – both in pharma and at diagnostics companies, in the lab and on the business side. She believes that the challenges of diagnostic technology fully impacting patient care are more commercial than technical, and conceived of ALVA10 to create a mechanism to pull technology into healthcare by aligning incentives through data. She regularly speaks on issues regarding advancement of technology in healthcare, is on the Board of Directors for two diagnostic companies and writes a column on the value of diagnostics for the Journal of Precision Medicine.

Guest Host:

Dr. William S. Smith is Pioneer’s Visiting Fellow in the Life Sciences. Dr. Smith has 25 years of experience in government and in corporate roles. His career includes senior staff positions for the Republican House leadership on Capitol Hill, the White House Office of National Drug Control Policy, and the Massachusetts Governor’s office where he served under Governors Weld and Cellucci. He spent ten years at Pfizer Inc as Vice President of Public Affairs and Policy where he was responsible for Pfizer’s corporate strategies for the U.S. policy environment. He later served as a consultant to major pharmaceutical, biotechnology and medical device companies. Dr. Smith earned his PhD in political science with distinction at The Catholic University of America.

Get new episodes of Hubwonk in your inbox!

Recent episodes:

Medicaid’s Massive Miasma: Taming Beacon Hill’s Burgeoning Budget Beast

Marc Joffe, a state policy analyst at the Cato Institute, talks about his research on Medicaid's cost and size. They explore how Massachusetts can control spending growth while protecting other priorities.

Baystate Budget Blues: Declining Revenue Causes Concern

Joe Selvaggi engages in a conversation with Pioneer Institute’s Eileen McAnneny, Senior Fellow for Economic Opportunity, to analyze the status of the 2024 budget. They compare actual revenue and spending with pre-July 1 estimates, investigating potential reasons for any surpluses or shortfalls. They also dive into policy implications for legislators as they approach fiscal 2025.

Smothering Gas Exports: President Sides with Environmentalists Over Environment

Dr. Benjamin Zycher, a senior fellow at the American Enterprise Institute, talks on the impact of President Biden's executive order to halt liquefied natural gas export approvals. He explores potential economic impacts, the response from trading partners, and the negligible effect on climate.

U.S. Manufacturing Health: Does the U.S. Need an Industrial Policy?

Scott Lincicome from the Cato Institute discusses the U.S. manufacturing industry, international trade, and industrial policy. He dispels the myth of manufacturing decline, highlighting sector evolution and productivity. The conversation moves to industrial policy, emphasizing the need for targeted protection and cautioning against broad subsidization due to potential inefficiencies.

Challenging Government Prerogatives: SCOTUS Reconsiders Deference to Executive Agencies

Joe Selvaggi engages in a conversation with legal scholar Ilya Shapiro from the Manhattan Institute regarding the Loper Bright Enterprises Supreme Court case that questions the Chevron Doctrine. This doctrine instructs judges to defer to government agencies in situations where laws are silent or unclear.

Harvard’s Sullied Halo: Journalists Teach Lesson on Plagiarism

Joe Selvaggi talks with investigative reporter Chris Brunet about his role investigating and exposing former Harvard President Claudine Gay’s academic plagiarism, a story that lead to her eventual resignation.

Drug Discount Distortions: How Middlemen Increase Costs and Reduce Access

Joe Selvaggi talks with Drs. Bill Smith and Robert Popovian about how the complex system of rebates from drug companies to insurance firms serve to increase costs and reduce access for patients.

Boston’s Building Bargain: Coaxing Commercial Conversions to Condos

Joe Selvaggi discusses the strategic goals of Boston's Downtown Office to Residential Conversion Pilot Program with Arthur Jemison, the head of BPDA planning. The aim is to transform underutilized offices in Downtown into vibrant places to live.

SCOTUS Wealth Tax: Are Appreciated Assets Income?

Joe Selvaggi talks with CATO Institute constitutional scholar Thomas Berry about the recently argued Moore v. U.S.A. case, which challenges the idea that income must be realized before it can be taxed.

Busting Big Business: Antitrust Comes for Google and Big Sandwich

Joe Selvaggi talks with Dr. Brian Albrecht, an economists with the International Center for Law and Economics. They separate fact from fiction when it comes to the public’s and politicians’ concerns over allegedly anti-consumer practices of big business and discuss when antitrust action by the federal government is justified.